These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37470295)

  • 41. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome.
    Nickel JC; Atkinson G; Krieger JN; Mills IW; Pontari M; Shoskes DA; Crook TJ
    Urology; 2012 Nov; 80(5):1105-10. PubMed ID: 23010344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials.
    Fan ZR; Ma JX; Wang Y; Chen HT; Lang S; Ma XL
    Clin Rheumatol; 2021 Jun; 40(6):2155-2165. PubMed ID: 33159281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis.
    Atkinson J; Edwards RA; Bonfanti G; Barroso J; Schnitzer TJ
    Adv Ther; 2023 Jan; 40(1):252-264. PubMed ID: 36301512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.
    Bramson C; Herrmann DN; Carey W; Keller D; Brown MT; West CR; Verburg KM; Dyck PJ
    Pain Med; 2015 Jun; 16(6):1163-76. PubMed ID: 25594611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
    Da JLW; Merker VL; Jordan JT; Ly KI; Muzikansky A; Parsons M; Wolters PL; Xu L; Styren S; Brown MT; Plotkin SR
    Contemp Clin Trials; 2022 Oct; 121():106900. PubMed ID: 36038003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor.
    Butt M; Evans M; Bowman CJ; Cummings T; Oneda S; Shelton D; Zorbas M
    Toxicol Sci; 2014 Dec; 142(2):463-76. PubMed ID: 25326242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
    Bannwarth B; Kostine M
    Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of tanezumab in the treatment of pain from bone metastases.
    Sopata M; Katz N; Carey W; Smith MD; Keller D; Verburg KM; West CR; Wolfram G; Brown MT
    Pain; 2015 Sep; 156(9):1703-1713. PubMed ID: 25919474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.
    Hunter DJ; Schnitzer TJ; Hall J; Semel D; Davignon I; Cappelleri JC; Bushmakin AG; Abraham L
    Osteoarthr Cartil Open; 2022 Sep; 4(3):100294. PubMed ID: 36474952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues.
    Bélanger P; West CR; Brown MT
    J Toxicol Sci; 2018; 43(1):1-10. PubMed ID: 29415946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study.
    Mont MA; Carrino JA; Nemeth MA; Burr A; Yamabe T; Viktrup L; Brown MT; West CR; Verburg KM
    Surg Technol Int; 2021 May; 38():467-477. PubMed ID: 34043229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.
    Zhao D; Luo MH; Pan JK; Zeng LF; Liang GH; Han YH; Liu J; Yang WY
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X211067639. PubMed ID: 35069811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
    Konno SI; Nikaido T; Markman JD; Ohta M; Machida T; Isogawa N; Yoshimatsu H; Viktrup L; Brown MT; West CR; Verburg KM
    Pain Manag; 2022 Apr; 12(3):323-335. PubMed ID: 34786956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.
    Hochberg MC
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S18-21. PubMed ID: 25527216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
    Yu Y; Lu ST; Sun JP; Zhou W
    Pain Med; 2021 Mar; 22(3):585-595. PubMed ID: 33141224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.